Show simple item record

dc.contributor.authorTejada, Miguel Ángel
dc.contributor.authorMontilla-García, Ángeles
dc.contributor.authorGonzález Cano, Rafael 
dc.contributor.authorBravo Caparrós, Inmaculada
dc.contributor.authorRuiz Cantero, María del Carmen 
dc.contributor.authorNieto López, Francisco Rafael 
dc.contributor.authorCobos del Moral, Enrique José 
dc.date.accessioned2021-03-11T13:30:55Z
dc.date.available2021-03-11T13:30:55Z
dc.date.issued2018-05
dc.identifier.citationTejada MÁ, Montilla-García Á, González-Cano R, Bravo-Caparrós I, Ruiz-Cantero MC, Nieto FR, Cobos EJ. Targeting immune-driven opioid analgesia by sigma-1 receptors: Opening the door to novel perspectives for the analgesic use of sigma-1 antagonists. Pharmacol Res. 2018 May;131:224-230es_ES
dc.identifier.urihttp://hdl.handle.net/10481/67118
dc.description.abstractImmune cells have a known role in pronociception, since they release a myriad of inflammatory algogens which interact with neurons to facilitate pain signaling. However, these cells also produce endogenous opioid peptides with analgesic potential. The sigma-1 receptor is a ligand-operated chaperone that modulates neurotransmission by interacting with multiple protein partners, including the µ-opioid receptor. We recently found that sigma-1 antagonists are able to induce opioid analgesia by enhancing the action of endogenous opioid peptides of immune origin during inflammation. This opioid analgesia is seen only at the inflamed site, where immune cells naturally accumulate. In this article we review the difficulties of targeting the opioid system for selective pain relief, and discuss the dual role of immune cells in pain and analgesia. Our discussion creates perspectives for possible novel therapeutic uses of sigma-1 antagonists as agents able to maximize the analgesic potential of the immune systemes_ES
dc.description.sponsorshipUniversity of Granadaes_ES
dc.description.sponsorshipMartín Escudero postdoctoral programes_ES
dc.description.sponsorshipFPU grants from the Spanish Ministry of Economy and Competitiveness (MINECO)es_ES
dc.description.sponsorshipJuan de la Cierva-Incorporación postdoctoral grant from MINECOes_ES
dc.description.sponsorshipMINECO [grant number SAF2016-80540-R]es_ES
dc.description.sponsorshipJunta de Andalucía (grant CTS109)es_ES
dc.description.sponsorshipFEDER fundses_ES
dc.language.isoenges_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectsigma-1 receptorses_ES
dc.subjectendogenous opioid peptideses_ES
dc.subjectanalgesiaes_ES
dc.subjectimmune cellses_ES
dc.subjectneuro-immune interactionses_ES
dc.titleTARGETING IMMUNE-DRIVEN OPIOID ANALGESIA BY SIGMA-1 RECEPTORS: OPENING THE DOOR TO NOVEL PERSPECTIVES FOR THE ANALGESIC USE OF SIGMA-1 ANTAGONISTSes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.projectIDMINECO [grant number SAF2016-80540-R]es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.phrs.2018.02.008
dc.type.hasVersioninfo:eu-repo/semantics/submittedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España